Program
IDP-121
A development code. Also written as “IDP-121 Lotion” and “IDP 121 Lotion”.
Its studies are mostly in Acne Vulgaris · Small Cell Lung Carcinoma · Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 50 open or running | phase 3since Jul 2, 2015 | Jul 2, 2015 | none ahead |
| IDP Discovery Pharma S.L. | 22 open or running | phase 2since May 3, 2023 | May 3, 2023 | Jul 30, 2028phase 2 · NCT07864207 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 2, 2015First study: phase 3 study in Acne VulgarisNew to Bausch Health CompaniesBausch Health Companies · NCT02491060 · 800 enrolled
- Aug 26, 2015Phase 3 study in Acne VulgarisBausch Health Companies · NCT02535871 · 800 enrolled
- Jul 6, 2016Phase 1 study in Acne VulgarisBausch Health Companies · NCT02849860 · 20 enrolled · United States
- Oct 11, 20162 phase 3 studies in Acne VulgarisBausch Health Companies · NCT02965456, NCT02932306
- May 3, 2023IDP Discovery Pharma S.L.'s first study: phase 2 study in Multiple MyelomaNew to IDP Discovery Pharma S.L.IDP Discovery Pharma S.L. · NCT05908409 · 37 planned · Spain
- Sep 29, 2026Phase 2 study in Small Cell Lung CarcinomaIDP Discovery Pharma S.L. · NCT07864207 · 60 planned · Spain
Ahead
- Jul 30, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaIDP Discovery Pharma S.L. · NCT07864207
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07864207Small Cell Lung Carcinoma · Spain | 2 | Recruiting | IDP Discovery Pharma S.L. | Jul 30, 2028 | 60 |
| NCT05908409Multiple Myeloma · Spain | 2 | Recruiting | IDP Discovery Pharma S.L. | Dec 22, 2025 | 37 |
| NCT02965456Acne Vulgaris · United States | 3 | Completed | Bausch Health Companies | Feb 23, 2017 | 820 |
| NCT02932306Acne Vulgaris · United States | 3 | Completed | Bausch Health Companies | Feb 22, 2017 | 820 |
| NCT02849860Acne Vulgaris · United States | 1 | Completed | Bausch Health Companies | Sep 2016 | 20 |
| NCT02535871Acne Vulgaris | 3 | UNKNOWN | Bausch Health Companies | Jul 2016 | 800 |
| NCT02491060Acne Vulgaris | 3 | UNKNOWN | Bausch Health Companies | Jul 2016 | 800 |
How it is read
Names in the registry
- “IDP-121 Lotion”, 4 entries
- “IDP-121”, 2 entries
- “IDP 121 Lotion”, 1 entry
Codes read as this program: IDP121.
Conditions, from the studies’ own filings
- Acne Vulgaris, 5 studies
- Small Cell Lung Carcinoma, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.